The Central South University Xiang Ya Hospital
Changsha, China
NCT Number: NCT05787041
The study was a single-center, randomized, open-access, two-crossover, single-dose study design with 16 subjects to evaluate the pharmacokinetics of a high-fat diet on a single dose of oral AD16 tablets in healthy Chinese adults and the safety of a single dose of oral AD16 tablets in healthy Chinese adults.
Compared with fasting administration, a high-fat diet reduced the rate of AD16 tablet absorption in healthy adult subjects and had no effect on overall exposure to AD16.
The elimination and distribution characteristics of AD16 in vivo were similar under the conditions of feeding and fasting administration.
A single dose of AD16 tablets after fasting and high fat diet showed good safety.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Changsha, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
Exclusion criteria
AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
Time frame: Up to Day 10
Maximum (peak) plasma drug concentration
Time frame: Up to Day 10
Area under the plasma concentration-time curve(AUC) from time zero to time t
Time frame: Up to Day 10
Area under the plasma concentration-time curve(AUC) from time zero to infinity
Time frame: Up to Day 10
Elimination half-life (to be used in a one-compartment or noncompartmental model)
Time frame: Up to Day 10
Time to reach the maximum (peak) plasma concentration following drug administration
Time frame: Up to Day 10
CL/F is defined as the ratio of total clearance(CL) to bioavailability(F).
Time frame: Up to Day 10
Apparent volume of distribution after non-intravenous administration
Time frame: Up to Day 10
Mean residence time(MRT)
Time frame: Up to Day 10
Terminal disposition rate constant/terminal rate constant
Time frame: day-7 to day 10
The number of adverse events
Time frame: day-7 to day 10
The number of serious adverse events
Time frame: day-7 to day-1 and day10
Laboratory tests include blood routine, blood biochemistry, coagulation function and urine routine
Time frame: day-7 to day3 and day7 to day10
vital signs include Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication.
Time frame: day-7 to day-1 and days3 、10
abnormal 12- Lead ECG
Time frame: day-7 to day-1 and day10
The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication.
Time frame: Up to Day 10
Any concomitant medication
South China Center For Innovative Pharmaceuticals
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04865172
Alzheimer Disease, Brain Diseases
Paris, France
View Trial DetailsNCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT05529706
Alzheimer Disease, Brain Diseases
San Francisco, California, United States
View Trial Details